Lazard Asset Management
ADVM

Lazard Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

Lazard Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17
Closed – – 2281
2024
Q4 		$0 Hold
17
– – ﹤0.01% 2259
2024
Q3 		$0 Sell
17
-29
-63% -$211 ﹤0.01% 2247
2024
Q2 		$0 Sell
46
-654
-93% -$6.08K ﹤0.01% 2209
2024
Q1 		$9K Sell
700
-293
-30% -$4.46K ﹤0.01% 1872
2023
Q4 		$7K Sell
993
-56
-5% -$511 ﹤0.01% 2105
2023
Q3 		$15K Buy
1,049
+43
+4% +$772 ﹤0.01% 2126
2023
Q2 		$15K Buy
+1,006
New +$10.6K ﹤0.01% 2144
2021
Q2 		– Sell
-11
Closed -$1K – 1945
2021
Q1 		$1K Hold
11
– – ﹤0.01% 1820
2020
Q4 		$1K Buy
+11
New +$1.36K ﹤0.01% 1815
2015
Q1 		– Sell
-11
Closed -$5K – 1114
2014
Q4 		$5K Buy
+11
New +$4.24K ﹤0.01% 1099

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lazard Asset Management's ADVM Position: Q1 2025 in Review

Lazard Asset Management sold out of Adverum Biotechnologies (ADVM) in Q1 2025, closing a stake of 17 shares.

Lazard Asset Management first reported a position in ADVM in Q4 2014 and held it in 10 quarters. The position peaked at $15K in Q3 2023. 70 funds tracked by Wall St. Rank hold ADVM as of Q1 2025.

  • Lazard Asset Management reported no remaining Adverum Biotechnologies position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 17 Adverum Biotechnologies shares in Q1 2025.
  • Lazard Asset Management first reported a position in Adverum Biotechnologies in Q4 2014 and held it in 10 quarters.
  • Lazard Asset Management's Adverum Biotechnologies position peaked at $15K in Q3 2023.
  • 70 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.